**Impact of High on-treatment Platelet Reactivity after Angioplasty in Patients with Peripheral Arterial Disease**

**Short title: HTPR in PAD Patients**

Lucas Busch MD1\*; Manuel Stern MD1\*; Lisa Dannenberg MD1; Philipp Mourikis1, Michael Gröne MD1; Göksen Özaslan, MD1; Yvonne Heinen MD1; Christian Heiss MD2; Roberto Sansone MD1, Amin Polzin MD1, Malte Kelm MD1

Supplementary appendix

**Supplementary Table 1:** MALE, MACCE and Bleeding Events during 6 months Follow-up

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **All****(102)** | **Dual****HTPR (11)** | **HTPR to clopidogrel****(37)** | **HTPR to aspirin** **(11)** | **Responder****(43)** | **p-Value****LogRank for trend** |
| **MALE – no. (%)** | **13 (13)** | **3 (27)** | **6 (16)** | **1 (9)** | **3 (7)** | **0.05** |
|  Stent-thrombosis | **8 (8)** | **2 (18)** | **5 (14)** | **0 (0)** | **1 (2)** | **0.02** |
|  Re-stenosis  | 3 (3) | 1 (9) | 0 (0) | 1 (9) | 1 (2) | 0.24 |
|  Vessel re-occlusion | 2 (2) | 0 (0) | 1 (3) | 0 (0) | 1 (2) | 0.9 |
| **Amputation – no. (%)** | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | **-** |
| **MACCE – no. (%)** |
|  Myocardial infarction | 2 (2) | 0 (0) | **2 (6)** | 0 (0) | 0 (0) | **n.a.** |
|  Stroke/TIA | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | **-** |
|  PCI | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | **-** |
|  Death | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | **-** |
| **Bleeding – no. (%)** |
|  BARC 2 | 2 (2) | 0 (0) | **1 (3)** | 0 (0) | 0 (0) | **n.a.** |
|  BARC 3 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | **-** |
|  BARC 4 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | **-** |
|  BARC 5 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | **-** |

HTPR= High on-treatment platelet reactivity; MALE= major adverse limb events; MACCE=Major adverse cardio- and cerebrovascular events; TIA=transient ischemic attack; PCI= percutaneous coronary intervention; BARC= bleeding academic research consortium classification

**Supplementary Table 2:** Multivariate logistic regression analysis for the occurrence of MALE in dependence from diabetes, creatinin, body mass index and age as well as in dependence from procedural details.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   | **Beta coefficient** | **p-Value** | **OR** | **95% C.I.**  |
| **Lower** | **Upper** |
| **Comorbidities** | Dual HTPR | **1.92** | **0.05** | **6.79** | **0.98** | **47.16** |
| Diabetes | 0.09 | 0.93 | 0.91 | 0.13 | 6.35 |
| Creatinin | 0.64 | 0.63 | 0.53 | 0.04 | 6.96 |
| Body Mass Index | 0.06 | 0.45 | 0.94 | 0.80 | 1.10 |
| Age | 0.03 | 0.57 | 0.97 | 0.87 | 1.08 |
|  |  |  |  |  |  |  |
|   | **Beta coefficient** | **p-Value** | **OR** | **95% C.I.** |
| **Lower** | **Upper** |
| **Procedural Details** | Dual HTPR | **2.72** | **0.04** | **15.20** | **1.14** | **202.51** |
| Multilevel Revascularization | 2.85 | 0.12 | 0.06 | 0.01 | 2.19 |
| Number of Stents | 0.74 | 0.19 | 2.09 | 0.70 | 6.20 |
| Number of Drug eluting Ballon | 1.23 | 0.15 | 3.44 | 0.64 | 18.36 |
| Number of Lesions | 1.52 | 0.18 | 0.22 | 0.02 | 2.03 |
| Chronic total occlusions revascularization | 1.04 | 0.47 | 0.35 | 0.02 | 6.03 |
| Leg (right, left, both sides) | 2.34 | 0.08 | 0.10 | 0.01 | 1.36 |

HTPR= High on treatment platelet reactivity